{
    "clinical_study": {
        "@rank": "4868", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "LX4211 800 mg"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "LX4211 2000 mg"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Active Comparator", 
                "description": "moxifloxacin 400 mg"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000\n      mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects."
        }, 
        "brief_title": "Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects \u226518 to \u226455 years of age\n\n          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140\n             mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm\n\n          -  Body mass index (BMI) \u226518 and \u226435 kg/sq m\n\n          -  Able and willing to provide written informed consent\n\n          -  Nonsmoker and has not used any tobacco products for at least 3 months prior to\n             Screening\n\n          -  Willing to adhere to the prohibitions and restrictions specified in this protocol\n\n          -  Able to tolerate prolonged periods of quiet, motionless, supervised rest\n\n        Exclusion Criteria:\n\n          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)\n             within 5 days of dosing\n\n          -  Use of any investigational agent or study treatment within 30 days prior to Screening\n\n          -  Use of any protein or antibody-based therapeutic agents within 3 months prior to\n             Screening\n\n          -  Prior exposure to LX4211\n\n          -  Daily use of cigarettes or any tobacco products within 3 months prior to Screening\n             and while participating in the study\n\n          -  History of any major surgery within 6 months prior to Screening\n\n          -  History of any serious adverse reaction or hypersensitivity to any inactive component\n             of LX4211\n\n          -  History of renal disease or significantly abnormal kidney function tests\n\n          -  History of hepatic disease or significantly abnormal liver function tests\n\n          -  Women who are breastfeeding or are planning to become pregnant during the study\n\n          -  History of any active infection within 14 days prior to Screening\n\n          -  History of alcohol or substance abuse within 2 years prior to Screening\n\n          -  History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1\n             or HIV-2\n\n          -  Presence of clinically significant physical, laboratory, or ECG findings (eg, QTcF\n             >450 msec for females and QTcF >430 msec for males) at Screening\n\n          -  >30 premature ventricular beats per hour on the telemetry ECG monitoring at Day -2 of\n             Period 1\n\n          -  History of additional risk factors for the presence of a family history of Short QT\n             Syndrome, Long QT Syndrome, sudden unexplained death at a young age (<=40 years),\n             drowning or sudden infant death syndrome in a first degree relative (ie, biological\n             parent, sibling, or child)\n\n          -  Any skin condition likely to interfere with ECG electrode placement or adhesion\n\n          -  Any skin condition likely to interfere with ECG electrode placement or adhesion\n\n          -  Donation or loss of >400 mL of blood or blood product within 3 months prior to\n             Screening\n\n          -  Positive urine glucose during Screening\n\n          -  Positive pregnancy test during Screening\n\n          -  Positive urine screen for drugs of abuse during Screening\n\n          -  Positive urine test for alcohol during Screening\n\n          -  Inability or difficulty swallowing whole tablets or capsules\n\n          -  Unable or unwilling to communicate or cooperate with the Investigator for any reason"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913002", 
            "org_study_id": "LX4211.1-109-NRM", 
            "secondary_id": "LX4211.109"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B", 
                    "Treatment C", 
                    "Treatment D"
                ], 
                "intervention_name": "LX4211 800 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B", 
                    "Treatment C", 
                    "Treatment D"
                ], 
                "intervention_name": "LX4211 2000 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B", 
                    "Treatment C", 
                    "Treatment D"
                ], 
                "intervention_name": "moxifloxacin 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B", 
                    "Treatment C", 
                    "Treatment D"
                ], 
                "intervention_name": "LX4211 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }, 
                "name": "Lexicon Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: A Thorough QT Study", 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Ikenna (Ike) Ogbaa, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in QTc intervals", 
            "safety_issue": "No", 
            "time_frame": "Day -1, Day 1 of each period (2, 3, 4)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913002"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects experiencing an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 87 days"
            }, 
            {
                "measure": "Plasma concentrations of LX4211", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of each Period: predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing time on Day 1 hours"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}